PMID: 7543701Aug 1, 1995Paper

Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy

Seminars in Oncology
A D SeidmanL Norton

Abstract

The novel chemotherapeutic agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has received more attention than perhaps any other drug in the past two decades in its development for the treatment of breast cancer. Its unique mechanism of action, demonstrated safety profile, and significant antitumor activity in thousands of patients treated in clinical trials thus far have led to recent US Food and Drug Administration approval of its use against chemotherapy-refractory metastatic breast cancer. This report will summarize the series of clinical investigations with paclitaxel in patients with metastatic breast cancer that have been completed over the past 3 years at Memorial Sloan-Kettering Cancer Center and address present and future avenues of research.

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A YounesL North
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
J A SchneiderS M Larson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
W P McGuireG Photopulos
© 2021 Meta ULC. All rights reserved